Table 2.
Reported clinical trials of targeted therapies for ES.
| Study | Phase | Enrichment of Molecular target |
Treatment Arms | No. of Patients |
RR (%) | Median PFS (mo) |
Median OS (mo) |
|---|---|---|---|---|---|---|---|
| IGF-1R | |||||||
| Kurzrock et al.17 | I | No | R1507 | 9 | 22.2% | N/R | N/R |
| Pappo et al.18 | II | No | R1507 | 115 | 9.6% | 1.3mo | 7.6mo |
| Tolcher et al.19 | I | No | AMG 479 | 12 | 16.7% | N/R | N/R |
| Tap et al.20 | II | No | AMG 479 | 19 | 5.3% | 7.9mo | N/R |
| Olmos et al.21 | I | No | figitumumab | 16 | 12.5% | N/R | N/R |
| Juergens et al.22 | I II |
No No |
figitumumab figitumumab |
16 106 |
6.3% 14.2% |
N/R 1.9mo |
N/R 8.9mo |
| Malempati et al.23 | I/II | No | cixutumamab | 35 | 8.6% | N/R | N/R |
| mTOR | |||||||
| Mita et al.24 | I | No | deforolimus | 1 | 100.0% | N/R | N/R |
| Bagatell et al.25 | I | No | temsirolimus +irinotecan +temozolomide |
7 | 0% | N/R | N/R |
| mTOR combination therapy | |||||||
| Naing et al.26 | I | No | Cixutumumab +temsirolimus |
17 | 11.8% | N/R | 12.3mo |
| Schwartz et al.27 | II | No | cixutumumab+ temsirolimus |
27 | 14.8% | 7.5weeks | 16.2mo |
| Kit/PDGFR | |||||||
| Bond et al.28 | II | No | imatinib mesylate | 24 | 4.2% | N/R | N/R |
| Chao et al.29 | II | IHC level | imatinib mesylate | 5 | 20.0% | N/R | N/R |
| EGFR | |||||||
| Daw et al.30 | I | No | gefitinib | 3 | 33.3% | N/R | N/R |
| VEGFR | |||||||
| Fox et al.31 | I | cediranib | 3 | 33.3% | N/R | N/R | |
N/R: not reported